Boehringer Ingelheim, Lilly initiate EMPULSE study of Jardiance for acute heart failure
German pharmaceutical firm Boehringer Ingelheim and US-based Eli Lilly have partnered to initiate EMPULSE program, the sixth phase III study of Jardiance (empagliflozin) for heart failure. The study